# Clostridium butyricum MIYAIRI 588 **Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/clostridium-butyricum-miyairi-588 **Data Source:** Hermetica Superfoods Ingredient Encyclopedia **Updated:** 2026-03-18 **Evidence Score:** 8 / 10 **Category:** Other **Also Known As:** Clostridium butyricum, C. butyricum, CBM 588, Miyairi 588, Butyric acid bacteria, Spore-forming probiotic, Clostridial probiotic ## Overview Clostridium butyricum MIYAIRI 588 is a spore-forming probiotic strain that produces butyric acid in the colon to support [digestive health](/ingredients/condition/gut-health) and [immune function](/ingredients/condition/immune-support). This beneficial bacterium strengthens the intestinal barrier and modulates [inflammatory](/ingredients/condition/inflammation) responses through short-chain fatty acid production. ## Health Benefits - Enhances gut health by producing butyric acid, which nourishes colon cells and improves bowel regularity. This promotes a healthy digestive system. - Reduces [inflammation](/ingredients/condition/inflammation) by modulating immune responses, potentially lowering the risk of chronic inflammatory diseases. - Supports metabolic health by influencing fat [metabolism](/ingredients/condition/weight-management), which can aid in weight management. - Boosts [immune function](/ingredients/condition/immune-support) by stimulating the production of beneficial short-chain fatty acids, enhancing the body's defense mechanisms. - Improves [mental clarity](/ingredients/condition/cognitive) by interacting with the gut-brain axis, potentially reducing symptoms of anxiety and depression. - Supports [liver health](/ingredients/condition/detox) by reducing liver fat accumulation, promoting detoxification processes. - Enhances [skin health](/ingredients/condition/skin-health) by reducing systemic inflammation, leading to clearer, more radiant skin. ## Mechanism of Action Clostridium butyricum MIYAIRI 588 ferments dietary fiber to produce butyric acid, which serves as the primary energy source for colonocytes and strengthens tight junction proteins in the intestinal barrier. Butyric acid activates GPR41 and GPR43 receptors on immune cells, promoting regulatory [T-cell](/ingredients/condition/immune-support) differentiation and reducing [pro-inflammatory cytokine](/ingredients/condition/inflammation) production. The strain also produces vitamin B12 and competes with pathogenic bacteria for colonization sites. ## Clinical Summary Human studies with Clostridium butyricum MIYAIRI 588 include randomized controlled trials in patients with irritable bowel syndrome and antibiotic-associated diarrhea. A 12-week study of 60 IBS patients showed 40% improvement in abdominal pain scores compared to placebo. Research in elderly patients demonstrated reduced duration of antibiotic-associated diarrhea from 5.2 to 2.8 days. However, most clinical evidence comes from small-scale studies, and larger trials are needed to confirm therapeutic benefits. ## Dosage & Preparation Consult a healthcare provider for appropriate dosage recommendations. ## Safety & Drug Interactions Clostridium butyricum MIYAIRI 588 is generally well-tolerated with mild gastrointestinal symptoms like bloating or gas being the most common side effects. The strain may theoretically interact with broad-spectrum antibiotics, which could reduce [probiotic](/ingredients/condition/gut-health) viability. Immunocompromised individuals should consult healthcare providers before use due to potential risk of bacteremia. Safety during pregnancy and breastfeeding has not been established through clinical trials. ## Scientific Research Research, including RCTs, indicates that Clostridium butyricum can help improve gut health and treat conditions like irritable bowel syndrome and ulcerative colitis. ## Historical & Cultural Context Clostridium butyricum has been used in traditional Asian medicine for its digestive benefits and is now gaining popularity in Western [probiotic](/ingredients/condition/gut-health) formulations. ## Synergistic Combinations Lactobacillus casei, Bifidobacterium lactis, Inulin ## Frequently Asked Questions ### What is the effective dosage of Clostridium butyricum MIYAIRI 588? Clinical studies typically use doses ranging from 10-40 mg daily (approximately 10^7 to 10^8 CFU). Most research supports taking 20 mg twice daily with meals for optimal colonization and butyric acid production. ### How long does it take for Clostridium butyricum MIYAIRI 588 to work? Initial effects on bowel regularity may appear within 3-7 days of supplementation. However, significant improvements in digestive symptoms and inflammatory markers typically require 4-8 weeks of consistent use based on clinical studies. ### Can Clostridium butyricum MIYAIRI 588 survive stomach acid? Yes, this strain forms protective spores that resist stomach acid and bile salts, allowing viable bacteria to reach the colon. The spore-forming ability distinguishes it from vegetative probiotic strains that may be destroyed by gastric acid. ### What foods naturally contain Clostridium butyricum? Clostridium butyricum is naturally found in fermented foods like natto, some traditional Asian pickled vegetables, and certain aged cheeses. However, the specific MIYAIRI 588 strain is only available through targeted supplementation, not natural food sources. ### Does Clostridium butyricum MIYAIRI 588 need refrigeration? No, the spore form of Clostridium butyricum MIYAIRI 588 is shelf-stable at room temperature and does not require refrigeration. This makes it more convenient for storage and travel compared to vegetative probiotic strains that need cold storage. ### Is Clostridium butyricum MIYAIRI 588 safe for people with immunocompromised conditions? Clostridium butyricum MIYAIRI 588 is generally considered safe for most people, but individuals with severe immunocompromise (such as those with HIV/AIDS, organ transplant recipients, or those on immunosuppressant medications) should consult their healthcare provider before use. While this strain is non-pathogenic and has a long safety history in Japan, immunocompromised individuals may have different risk profiles. Medical supervision is recommended to determine if supplementation is appropriate for your specific condition. ### How does Clostridium butyricum MIYAIRI 588 compare to other butyrate-producing probiotics? Clostridium butyricum MIYAIRI 588 is one of the most well-researched and clinically-studied butyrate-producing strains, with decades of use and safety data primarily from Japanese healthcare systems. Unlike some other butyrate producers, this specific strain has demonstrated efficacy in human clinical trials for improving bowel regularity and reducing inflammatory markers. Other butyrate producers like Faecalibacterium prausnitzii may have theoretical benefits, but they are less stable as supplements and have less extensive human safety documentation than MIYAIRI 588. ### Can Clostridium butyricum MIYAIRI 588 help with specific digestive conditions like IBS or inflammatory bowel disease? Clinical research suggests Clostridium butyricum MIYAIRI 588 may benefit individuals with irritable bowel syndrome (IBS) by improving stool consistency and reducing abdominal discomfort through butyric acid production and immune modulation. However, evidence for inflammatory bowel diseases (Crohn's disease and ulcerative colitis) is more limited, and these conditions require professional medical management. If you have IBS or IBD, discuss supplementation with your gastroenterologist to ensure it complements your treatment plan appropriately. --- *Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com* *License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*